BeOne Medicines Dettes/EBITDA

Que fait BeOne Medicines ? BeOne Medicines AG operates as a biotechnology company focused on oncology medicines, developing and commercializing treatments for blood cancers and solid tumors. The company has three approved medicines: BRUKINSA, a second-generation small molecule inhibitor of Bruton’s Tyrosine Kinase (BTK) for blood cancers; tislelizumab, an anti-PD-1 antibody immunotherapy for solid tumors and blood cancers; and pamiparib, a selective small molecule inhibitor of PARP1 and PARP2. BRUKINSA is marketed in the United States, China, the European Union, the United Kingdom, Canada, and Australia, while the firm has in-licensed 13 approved medicines for the China market. The company generates revenue primarily through the sale of its approved oncology medicines to healthcare providers and hospitals globally. BRUKINSA, tislelizumab, and pamiparib are sold to oncology departments and cancer treatment centers, with BRUKINSA being distributed in multiple international markets. The firm also earns income from in-licensed medicines distributed in China, targeting domestic pharmaceutical companies and healthcare systems. BeOne Medicines AG's key customers include hospitals, oncology clinics, and pharmaceutical distributors in the United States, Europe, China, and other regions. The company's products are used by patients with various blood cancers and solid tumors, with BRUKINSA specifically addressing conditions like mantle cell lymphoma and chronic lymphocytic leukemia. The firm's commercial strategy focuses on expanding access to its medicines in global markets while leveraging in-licensed products for the Chinese market. BeOne Medicines est l'une des entreprises les plus populaires sur Eulerpool.